Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy)

Advances in immune checkpoint therapy and targeted therapy have led to improvement in overall survival for patients with advanced melanoma. Single agent checkpoint PD-1 blockade and combination with BRAF/MEK targeted therapy demonstrated benefit in overall survival (OS). Superior response rates have...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A., Blank, Christian, Dummer, Reinhard, Ernstoff, Marc S., Ferrone, Soldano, Fox, Bernard A., Gajewski, Thomas F., Garbe, Claus, Hwu, Patrick, Kalinski, Pawel, Krogsgaard, Michelle, Lo, Roger S., Luke, Jason J., Neyns, Bart, Postow, Michael A., Quezada, Sergio A., Teng, Michele W. L., Trinchieri, Giorgio, Testori, Alessandro, Caracò, Corrado, Osman, Iman, Puzanov, Igor, Thurin, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243582/
https://www.ncbi.nlm.nih.gov/pubmed/34193182
http://dx.doi.org/10.1186/s12967-021-02951-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243582/
https://www.ncbi.nlm.nih.gov/pubmed/34193182
http://dx.doi.org/10.1186/s12967-021-02951-x

Ejemplares similares